Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.41 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.41 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.41 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.40 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.40 |
| ▸ | CALCR | P30988 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723138 | 1.00 | RXFP1 (0.42) | RXFP1OPRM1OPRD1OPRK1ECE1 | |
| SCHEMBL13723037 | 0.98 | OPRM1 (0.44) | RXFP1OPRM1OPRD1OPRK1ECE1 | |
| SCHEMBL13724371 | 0.97 | OPRM1 (0.42) | RXFP1OPRM1OPRD1OPRK1ECE1 | |
| SCHEMBL13220270 | 0.96 | OPRM1 (0.41) | RXFP1OPRM1OPRD1OPRK1ECE1 | |
| SCHEMBL13723684 | 0.96 | RXFP1 (0.43) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL13722272 | 0.95 | VIPR1 (0.44) | RXFP1VIPR1VIPR2KEAP1 | |
| SCHEMBL13722475 | 0.95 | VIPR1 (0.44) | RXFP1VIPR1VIPR2KEAP1 | |
| SCHEMBL13723050 | 0.95 | VIPR1 (0.44) | RXFP1VIPR1VIPR2KEAP1 | |
| SCHEMBL13723414 | 0.94 | RXFP1 (0.45) | RXFP1ECE1GLP1RMUS81PTH1R | |
| SCHEMBL13723427 | 0.94 | RXFP1 (0.43) | RXFP1OPRM1OPRD1OPRK1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | RXFP1 355/4885OPRM1 1981/4885OPRD1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.